American Patients Seek Regenerative Medicine in Japan Due to Differing FDA Regulations
American patients are increasingly traveling to Japan for stem cell therapy, particularly for treatments involving culture-expanded autologous adipose-derived mesenchymal stem cells (ADSCs). This trend is driven by significant differences in regulatory frameworks between the U.S. Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare (MHLW). In the U.S., the FDA classifies culture-expanded stem cells as biological drugs requiring extensive licensing or investigational new drug applications, making them largely unavailable outside of registered clinical trials. Conversely, Japan's Act on the Safety of Regenerative Medicine (2014) allows licensed clinics to provide such treatments after committee review and notification to the MHLW. Clinics like Cell Grand Clinic in Osaka offer these therapies for conditions such as knee osteoarthritis, diabetes support, Alzheimer's disease, and age-related decline. The process typically involves two trips to Japan, with an initial consultation... 
